This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2000 Apr 29;355(9214):1474-5.

doi: 10.1016/S0140-6736(00)02155-3.

Choice of hormonal therapy for prostate cancer

D M Reese¹

Affiliations

PMID: 10801162
DOI: 10.1016/S0140-6736(00)02155-3

Comment

Choice of hormonal therapy for prostate cancer

D M Reese. Lancet. 2000.

. 2000 Apr 29;355(9214):1474-5.

doi: 10.1016/S0140-6736(00)02155-3.

Author

D M Reese¹

Affiliation

¹ Urologic Oncology Program, University of California San Francisco Mount Zion Cancer Center, 94115, USA.

PMID: 10801162
DOI: 10.1016/S0140-6736(00)02155-3

No abstract available

PubMed Disclaimer

Comment on

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
[No authors listed] [No authors listed] Lancet. 2000 Apr 29;355(9214):1491-8. Lancet. 2000. PMID: 10801170

Similar articles

[Hormonal treatment of advanced cancer of the prostate].
de Leval J. de Leval J. Rev Med Liege. 1991 Nov;46(11):577-82. Rev Med Liege. 1991. PMID: 1754776 Review. French. No abstract available.
Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer.
Simmons MN, Klein EA. Simmons MN, et al. Urology. 2009 Apr;73(4):697-705. doi: 10.1016/j.urology.2008.09.040. Epub 2009 Jan 30. Urology. 2009. PMID: 19185908 Review. No abstract available.
Compliance with hormonal treatment for prostate cancer.
Kaisary AV. Kaisary AV. Br J Hosp Med. 1996 Mar 20-Apr 2;55(6):359-66. Br J Hosp Med. 1996. PMID: 8696636 Review.
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
Klotz L, Schellhammer P, Carroll K. Klotz L, et al. BJU Int. 2004 Jun;93(9):1177-82. doi: 10.1111/j.1464-410x.2004.04803.x. BJU Int. 2004. PMID: 15180600 Review. No abstract available.
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Kijima T, et al. BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348

See all similar articles

Cited by

Tissue-selective therapy of cancer.
Blagosklonny MV. Blagosklonny MV. Br J Cancer. 2003 Oct 6;89(7):1147-51. doi: 10.1038/sj.bjc.6601256. Br J Cancer. 2003. PMID: 14520435 Free PMC article. Review.
Bicalutamide: in early-stage prostate cancer.
Carswell CI, Figgitt DP. Carswell CI, et al. Drugs. 2002;62(17):2471-79; discussion 2480-1. doi: 10.2165/00003495-200262170-00006. Drugs. 2002. PMID: 12421104 Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information